Eton Pharmaceuticals, Inc. (ETON)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $53.33
- As of
Kresmion compiles this page from ETON's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Eton Pharmaceuticals, Inc. (ETON): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-14.
See the full ETON dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ETON on one page. Preview it with sample data, then open it live with a free account.
Preview the ETON dossierActive signals for ETON
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 198.4%, EPS $0.35 vs $0.1173 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 51% of ETON (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +248% to ETON (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 68% of ETON (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +1129% to ETON (2026Q2)
FREE, NO ACCOUNT
Every signal on ETON, as it fires
You are seeing 5 of 12 signals recorded on ETON since 2026-05-26.
The five above landed across 2 days. The other 7 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ETON (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 29772L108 · 2026Q2 | $6.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 29772L108 · 2026Q2 | $4.2M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 29772L108 · 2026Q2 | $1.9M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 29772L108 · 2026Q2 | $1.8M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 29772L108 · 2026Q2 | $1.6M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ETON
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ETON against its peers
ETON's operating margin of -1.1% ranks in the 48th percentile of 19 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ETON | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 80.0M USD | 567M USD | 13 | 18 |
| Revenue YoY | n/a | -4.3% | n/a | 5 |
| Gross margin | 53.5% | 48.9% | 72 | 15 |
| Operating margin | -1.1% | -0.4% | 48 | 19 |
| Net margin | -5.8% | -6.4% | 53 | 19 |
| Return on equity | -17.6% | -8.7% | 44 | 16 |
| P / E | n/a | 13.3x | n/a | 5 |
| 1 year | 195.0% | -24.1% | 97 | 16 |
Peers (21): GTBIF, ALVO, CRON, HROW, PBH, PRGO, HCM, CURLF, RGC, AQST, INDV, EOLS, TLRY, VREOF, KMDA, NIKA, TKNO, KNSA, VRNO, CGC, ELTP. Left out: HYPMY (no annual filing), EVO (period gap), BORAY (no annual filing), LFCR (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ETON: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ETON on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ETON for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.